ES2637072T3 - Formulación parenteral de antibióticos macrólidos - Google Patents
Formulación parenteral de antibióticos macrólidos Download PDFInfo
- Publication number
- ES2637072T3 ES2637072T3 ES11754115.1T ES11754115T ES2637072T3 ES 2637072 T3 ES2637072 T3 ES 2637072T3 ES 11754115 T ES11754115 T ES 11754115T ES 2637072 T3 ES2637072 T3 ES 2637072T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- cem
- pharmaceutical composition
- agent
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31241710P | 2010-03-10 | 2010-03-10 | |
| US312417P | 2010-03-10 | ||
| PCT/US2011/027984 WO2011112864A1 (en) | 2010-03-10 | 2011-03-10 | Parenteral formulations of macrolide antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2637072T3 true ES2637072T3 (es) | 2017-10-10 |
Family
ID=44563855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11754115.1T Active ES2637072T3 (es) | 2010-03-10 | 2011-03-10 | Formulación parenteral de antibióticos macrólidos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20130045937A1 (https=) |
| EP (1) | EP2544537B1 (https=) |
| JP (1) | JP5890785B2 (https=) |
| CN (2) | CN109091489A (https=) |
| AU (1) | AU2011224238B2 (https=) |
| CA (1) | CA2792616A1 (https=) |
| DK (1) | DK2544537T3 (https=) |
| ES (1) | ES2637072T3 (https=) |
| PL (1) | PL2544537T3 (https=) |
| SI (1) | SI2544537T1 (https=) |
| WO (1) | WO2011112864A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1638549A4 (en) | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| EP2214484A4 (en) | 2007-10-25 | 2013-01-02 | Cempra Pharmaceuticals Inc | PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS |
| JP5711135B2 (ja) | 2008-10-24 | 2015-04-30 | センプラ ファーマシューティカルズ,インコーポレイテッド | 胃腸疾患を治療するための方法 |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| ES2608285T3 (es) | 2009-09-10 | 2017-04-07 | Cempra Pharmaceuticals, Inc. | Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC |
| MX361413B (es) | 2010-03-22 | 2018-12-05 | Cempra Pharmaceuticals Inc Star | Formas cristalinas de un macrólido y usos para las mismas. |
| CN102917708B (zh) | 2010-05-20 | 2015-11-25 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| EP2613630A4 (en) | 2010-09-10 | 2014-01-15 | Cempra Pharmaceuticals Inc | HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
| NZ700182A (en) * | 2012-03-27 | 2017-02-24 | Cempra Pharmaceuticals Inc | Parenteral formulations for administering macrolide antibiotics |
| AU2014239959A1 (en) * | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| CN105188712A (zh) | 2013-03-15 | 2015-12-23 | 森普拉制药公司 | 用于制备大环内酯抗菌剂的收敛方法 |
| JP6437523B2 (ja) | 2013-04-04 | 2018-12-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | マクロライドならびにそれらの調製および使用の方法 |
| EP3895724B1 (en) | 2013-05-22 | 2025-06-25 | Zensun (Shanghai) Science and Technology, Co., Ltd. | Extended release of neuregulin for treating heart failure |
| CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
| SG11201700827RA (en) * | 2014-08-05 | 2017-03-30 | Cempra Pharmaceuticals Inc | Powder oral suspension formulations of antibacterial agents |
| CN106998685A (zh) | 2014-10-08 | 2017-08-01 | 哈佛大学的校长及成员们 | 14‑元酮内酯及其制备和使用方法 |
| CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| EP3273969A4 (en) | 2015-03-25 | 2018-11-21 | President and Fellows of Harvard College | Macrolides with modified desosamine sugars and uses thereof |
| BR112021026480A2 (pt) * | 2019-06-28 | 2022-02-08 | Univ Texas | Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| NZ523693A (en) * | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| BR0307898A (pt) * | 2002-02-22 | 2004-12-07 | Pharmacia Corp | Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio |
| EP1638549A4 (en) * | 2003-03-10 | 2011-06-15 | Optimer Pharmaceuticals Inc | NEW ANTIBACTERIAL AGENTS |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| CN101045063B (zh) * | 2006-03-28 | 2011-01-26 | 广州朗圣药业有限公司 | 注射用克拉霉素水溶性制剂 |
| CN101129383B (zh) * | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
-
2011
- 2011-03-10 ES ES11754115.1T patent/ES2637072T3/es active Active
- 2011-03-10 DK DK11754115.1T patent/DK2544537T3/en active
- 2011-03-10 WO PCT/US2011/027984 patent/WO2011112864A1/en not_active Ceased
- 2011-03-10 EP EP11754115.1A patent/EP2544537B1/en not_active Not-in-force
- 2011-03-10 JP JP2012557258A patent/JP5890785B2/ja active Active
- 2011-03-10 AU AU2011224238A patent/AU2011224238B2/en not_active Ceased
- 2011-03-10 CN CN201811127818.4A patent/CN109091489A/zh active Pending
- 2011-03-10 CN CN2011800150681A patent/CN102811616A/zh active Pending
- 2011-03-10 PL PL11754115T patent/PL2544537T3/pl unknown
- 2011-03-10 CA CA2792616A patent/CA2792616A1/en not_active Abandoned
- 2011-03-10 SI SI201131266T patent/SI2544537T1/sl unknown
- 2011-03-10 US US13/583,556 patent/US20130045937A1/en not_active Abandoned
-
2018
- 2018-03-12 US US15/918,098 patent/US20190054059A1/en not_active Abandoned
-
2019
- 2019-12-02 US US16/700,384 patent/US20200276150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109091489A (zh) | 2018-12-28 |
| JP2013522229A (ja) | 2013-06-13 |
| PL2544537T3 (pl) | 2017-10-31 |
| AU2011224238A1 (en) | 2012-10-04 |
| SI2544537T1 (sl) | 2017-12-29 |
| US20190054059A1 (en) | 2019-02-21 |
| US20200276150A1 (en) | 2020-09-03 |
| EP2544537B1 (en) | 2017-05-10 |
| WO2011112864A1 (en) | 2011-09-15 |
| EP2544537A4 (en) | 2014-05-14 |
| CN102811616A (zh) | 2012-12-05 |
| US20130045937A1 (en) | 2013-02-21 |
| EP2544537A1 (en) | 2013-01-16 |
| JP5890785B2 (ja) | 2016-03-22 |
| AU2011224238B2 (en) | 2015-11-26 |
| CA2792616A1 (en) | 2011-09-15 |
| DK2544537T3 (en) | 2017-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2637072T3 (es) | Formulación parenteral de antibióticos macrólidos | |
| US10188674B2 (en) | Parenteral formulations for administering macrolide antibiotics | |
| ES2384451T3 (es) | Aplicación de levo-ornidazol en la preparación de un medicamento contra la infección de bacterias anaeróbicas . | |
| ES2356242T3 (es) | Preparación liofilizada conteniendo metilcobalamina y procedimiento de producción de esta preparación. | |
| ES3041708T3 (en) | Liquid pharmaceutical composition demonstrating excellent preservation efficacy | |
| EA022765B1 (ru) | Фармацевтическая композиция | |
| EP2303228B1 (en) | Fosphenytoin composition | |
| HK40002820A (en) | Parenteral formulations of macrolide antibiotics | |
| HK1179115A (en) | Parenteral formulations of macrolide antibiotics | |
| ES2346573T3 (es) | Composiciones de cefquinoma y metodos para su uso. | |
| HK1180184A (en) | Parenteral formulations of macrolide antibiotics | |
| HK1180184B (en) | Parenteral formulations of macrolide antibiotics | |
| KR20160090312A (ko) | 조산 조건의 치료에서 사용을 위한 용량 단위의 조합 | |
| BR112019017223A2 (pt) | macrolídeos contendo triazol e seus usos oftálmicos | |
| HK1208622B (zh) | 用於施用大环内酯抗生素的肠胃外制剂 |